Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 20.49% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $4.9 billion (up 26.51% YoY), and the FY2025 full-year result was $1.3 billion, up 27.26% from the prior year.
• Liabilities and Shareholders Equity held at $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $464.0 million in Q1 2022.
• A 5-year average of $876.4 million and a median of $847.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 64.53% in 2022 and increased 12.92% in 2024, its largest moves.
• Tracing HRMY's Liabilities and Shareholders Equity over 5 years: stood at $673.9 million in 2022, then gained by 20.42% to $811.4 million in 2023, then climbed by 23.14% to $999.2 million in 2024, then grew by 27.26% to $1.3 billion in 2025, then grew by 0.02% to $1.3 billion in 2026.
• Business Quant data shows HRMY's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.